Home Data Calendar Blog

HLTH

Tables

2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30

Common Stock Value 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NA NA NA NA

Weighted Average Number Of Diluted Shares Outstanding 153.70 151.87 151.08 NA 148.29 147.50 153.04 NA 39.30 26.24 25.90 NA 16.56

Weighted Average Number Of Shares Outstanding Basic 153.70 151.87 151.08 NA 148.29 147.50 146.53 NA 31.55 18.82 18.38 NA 16.56

Earnings Per Share Basic -0.31 -0.55 -0.62 -0.21 -0.45 -0.67 0.02 0.26 140.00 0.14 0.09 -1.18 -0.52

Earnings Per Share Diluted -0.31 -0.55 -0.62 -0.21 -0.45 -0.67 0.02 0.24 0.13 0.14 0.08 -1.18 -0.52

	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Common Stock Value	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	NA	NA	NA	NA
Weighted Average Number Of Diluted Shares Outstanding	153.70	151.87	151.08	NA	148.29	147.50	153.04	NA	39.30	26.24	25.90	NA	16.56
Weighted Average Number Of Shares Outstanding Basic	153.70	151.87	151.08	NA	148.29	147.50	146.53	NA	31.55	18.82	18.38	NA	16.56
Earnings Per Share Basic	-0.31	-0.55	-0.62	-0.21	-0.45	-0.67	0.02	0.26	140.00	0.14	0.09	-1.18	-0.52
Earnings Per Share Diluted	-0.31	-0.55	-0.62	-0.21	-0.45	-0.67	0.02	0.24	0.13	0.14	0.08	-1.18	-0.52

2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30

Revenue From Contract With Customer Excluding Assessed Tax 17.48 9.90 24.77 146.78 69.59 87.70 179.41 192.51 223.68 137.42 64.50 13.26 4.73

Revenues 17.48 9.90 24.77 146.78 69.59 87.70 179.41 192.51 223.68 137.42 64.50 13.26 4.73

Operating Costs And Expenses 82.18 95.29 120.61 185.40 137.00 190.16 176.56 169.12 136.30 72.72 49.74 31.36 13.23

Research And Development Expense 37.10 36.54 44.73 56.15 42.52 44.00 28.79 21.68 9.08 4.66 7.41 1.92 6.88

General And Administrative Expense 15.85 14.70 16.94 19.16 25.62 25.41 26.91 23.45 33.08 11.38 11.87 16.48 3.69

Selling And Marketing Expense 7.05 8.06 11.25 19.31 18.13 16.97 34.17 21.20 5.57 1.53 0.43 0.65 0.02

Operating Income Loss -64.70 -85.39 -95.85 -38.62 -67.41 -102.46 2.85 23.38 87.38 64.71 14.76 -18.09 -8.50

Interest Income Expense Nonoperating Net -0.30 -0.29 -0.22 -0.23 -0.35 -0.02 -0.05 -0.06 -1.79 -9.43 -0.54 -0.10 0.51

Income Tax Expense Benefit 4.73 NA NA -5.32 -1.05 -3.39 NA -10.62 30.10 12.05 1.23 NA NA

Net Income Loss -46.97 -83.86 -94.20 -31.51 -66.30 -99.05 2.80 34.23 19.35 19.81 13.03 -19.54 -8.54

Net Income Loss Available To Common Stockholders Basic NA NA NA -31.51 -66.30 -99.05 2.80 24.59 4.42 2.72 1.67 -19.54 -8.54

Net Income Loss Available To Common Stockholders Diluted NA NA NA -31.51 -66.30 -99.05 2.80 24.73 5.12 3.56 2.19 -19.54 -8.54

	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Revenue From Contract With Customer Excluding Assessed Tax	17.48	9.90	24.77	146.78	69.59	87.70	179.41	192.51	223.68	137.42	64.50	13.26	4.73
Revenues	17.48	9.90	24.77	146.78	69.59	87.70	179.41	192.51	223.68	137.42	64.50	13.26	4.73
Operating Costs And Expenses	82.18	95.29	120.61	185.40	137.00	190.16	176.56	169.12	136.30	72.72	49.74	31.36	13.23
Research And Development Expense	37.10	36.54	44.73	56.15	42.52	44.00	28.79	21.68	9.08	4.66	7.41	1.92	6.88
General And Administrative Expense	15.85	14.70	16.94	19.16	25.62	25.41	26.91	23.45	33.08	11.38	11.87	16.48	3.69
Selling And Marketing Expense	7.05	8.06	11.25	19.31	18.13	16.97	34.17	21.20	5.57	1.53	0.43	0.65	0.02
Operating Income Loss	-64.70	-85.39	-95.85	-38.62	-67.41	-102.46	2.85	23.38	87.38	64.71	14.76	-18.09	-8.50
Interest Income Expense Nonoperating Net	-0.30	-0.29	-0.22	-0.23	-0.35	-0.02	-0.05	-0.06	-1.79	-9.43	-0.54	-0.10	0.51
Income Tax Expense Benefit	4.73	NA	NA	-5.32	-1.05	-3.39	NA	-10.62	30.10	12.05	1.23	NA	NA
Net Income Loss	-46.97	-83.86	-94.20	-31.51	-66.30	-99.05	2.80	34.23	19.35	19.81	13.03	-19.54	-8.54
Net Income Loss Available To Common Stockholders Basic	NA	NA	NA	-31.51	-66.30	-99.05	2.80	24.59	4.42	2.72	1.67	-19.54	-8.54
Net Income Loss Available To Common Stockholders Diluted	NA	NA	NA	-31.51	-66.30	-99.05	2.80	24.73	5.12	3.56	2.19	-19.54	-8.54

2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30

Assets 492.29 523.86 608.56 694.58 825.04 914.08 983.77 940.06 921.98 NA NA 316.33 NA

Liabilities 103.46 100.68 112.70 118.09 235.08 273.70 258.63 233.31 267.61 NA NA 241.41 NA

Liabilities And Stockholders Equity 492.29 523.86 608.56 694.58 825.04 914.08 983.77 940.06 921.98 NA NA 316.33 NA

Stockholders Equity 388.83 423.18 495.86 576.49 589.96 640.37 725.14 706.75 654.38 -61.33 -85.27 -101.40 -84.98

	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Assets	492.29	523.86	608.56	694.58	825.04	914.08	983.77	940.06	921.98	NA	NA	316.33	NA
Liabilities	103.46	100.68	112.70	118.09	235.08	273.70	258.63	233.31	267.61	NA	NA	241.41	NA
Liabilities And Stockholders Equity	492.29	523.86	608.56	694.58	825.04	914.08	983.77	940.06	921.98	NA	NA	316.33	NA
Stockholders Equity	388.83	423.18	495.86	576.49	589.96	640.37	725.14	706.75	654.38	-61.33	-85.27	-101.40	-84.98

2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30

Assets Current 192.24 212.07 287.00 371.15 521.87 620.13 701.41 670.02 669.53 NA NA 183.70 NA

Cash And Cash Equivalents At Carrying Value 111.45 128.55 178.20 241.53 304.65 363.12 426.46 409.87 446.59 246.33 38.94 121.58 49.17

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 112.25 129.35 179.00 242.33 305.99 364.46 440.30 423.71 458.59 252.33 118.94 129.25 50.85

Accounts Receivable Net Current 1.32 1.71 9.80 18.75 24.78 54.01 75.83 104.59 90.19 NA NA 4.17 NA

Inventory Net 63.55 68.37 82.01 82.21 133.31 139.05 132.57 88.39 70.74 NA NA 36.84 NA

Inventory Finished Goods 39.18 41.89 45.06 37.87 74.44 73.67 60.77 46.09 21.22 NA NA 1.65 NA

Other Assets Current 5.25 3.33 4.57 12.13 13.44 12.19 9.81 7.45 2.09 NA NA 1.26 NA

	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Assets Current	192.24	212.07	287.00	371.15	521.87	620.13	701.41	670.02	669.53	NA	NA	183.70	NA
Cash And Cash Equivalents At Carrying Value	111.45	128.55	178.20	241.53	304.65	363.12	426.46	409.87	446.59	246.33	38.94	121.58	49.17
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents	112.25	129.35	179.00	242.33	305.99	364.46	440.30	423.71	458.59	252.33	118.94	129.25	50.85
Accounts Receivable Net Current	1.32	1.71	9.80	18.75	24.78	54.01	75.83	104.59	90.19	NA	NA	4.17	NA
Inventory Net	63.55	68.37	82.01	82.21	133.31	139.05	132.57	88.39	70.74	NA	NA	36.84	NA
Inventory Finished Goods	39.18	41.89	45.06	37.87	74.44	73.67	60.77	46.09	21.22	NA	NA	1.65	NA
Other Assets Current	5.25	3.33	4.57	12.13	13.44	12.19	9.81	7.45	2.09	NA	NA	1.26	NA

2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30

Amortization Of Intangible Assets 2.40 1.80 1.60 1.30 1.00 0.80 0.60 0.10 0.20 1.50 0.20 NA NA

Intangible Assets Net Excluding Goodwill 21.54 NA NA 16.87 NA NA NA NA NA NA NA NA NA

Finite Lived Intangible Assets Net 21.54 21.77 19.77 16.87 16.04 10.94 9.24 7.67 3.69 NA NA 2.04 NA

Other Assets Noncurrent 3.73 3.80 5.33 6.53 7.58 6.90 5.68 3.87 1.41 NA NA 0.18 NA

	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Amortization Of Intangible Assets	2.40	1.80	1.60	1.30	1.00	0.80	0.60	0.10	0.20	1.50	0.20	NA	NA
Intangible Assets Net Excluding Goodwill	21.54	NA	NA	16.87	NA	NA	NA	NA	NA	NA	NA	NA	NA
Finite Lived Intangible Assets Net	21.54	21.77	19.77	16.87	16.04	10.94	9.24	7.67	3.69	NA	NA	2.04	NA
Other Assets Noncurrent	3.73	3.80	5.33	6.53	7.58	6.90	5.68	3.87	1.41	NA	NA	0.18	NA

2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30

Liabilities Current 58.41 57.03 67.46 71.19 175.46 210.03 191.74 166.94 181.63 NA NA 155.90 NA

Accounts Payable Current 11.11 11.21 16.64 7.15 32.52 38.35 48.84 37.21 35.15 NA NA 23.85 NA

Accounts Payable And Accrued Liabilities Current 39.92 35.92 40.17 52.38 47.10 75.82 39.81 29.50 NA NA NA NA NA

Other Accrued Liabilities Current 6.07 6.34 7.89 5.55 3.15 10.84 8.54 6.37 NA NA NA NA NA

Taxes Payable Current NA NA NA NA NA NA 8.25 8.30 37.37 NA NA NA NA

Accrued Income Taxes Current 2.84 NA NA NA NA NA NA NA NA NA NA NA NA

Contract With Customer Liability Current 0.62 0.47 0.75 1.57 84.90 85.58 84.63 82.17 76.34 NA NA 115.75 NA

	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Liabilities Current	58.41	57.03	67.46	71.19	175.46	210.03	191.74	166.94	181.63	NA	NA	155.90	NA
Accounts Payable Current	11.11	11.21	16.64	7.15	32.52	38.35	48.84	37.21	35.15	NA	NA	23.85	NA
Accounts Payable And Accrued Liabilities Current	39.92	35.92	40.17	52.38	47.10	75.82	39.81	29.50	NA	NA	NA	NA	NA
Other Accrued Liabilities Current	6.07	6.34	7.89	5.55	3.15	10.84	8.54	6.37	NA	NA	NA	NA	NA
Taxes Payable Current	NA	NA	NA	NA	NA	NA	8.25	8.30	37.37	NA	NA	NA	NA
Accrued Income Taxes Current	2.84	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Contract With Customer Liability Current	0.62	0.47	0.75	1.57	84.90	85.58	84.63	82.17	76.34	NA	NA	115.75	NA

2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30

Other Liabilities Noncurrent 2.09 2.00 2.00 2.00 3.83 4.94 6.36 6.36 0.88 NA NA 4.50 NA

Operating Lease Liability Noncurrent 42.96 41.66 42.83 44.05 44.23 46.45 47.63 46.46 50.03 NA NA 10.47 NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Other Liabilities Noncurrent		2.09	2.00	2.00	2.00	3.83	4.94	6.36	6.36	0.88	NA	NA	4.50	NA
Operating Lease Liability Noncurrent		42.96	41.66	42.83	44.05	44.23	46.45	47.63	46.46	50.03	NA	NA	10.47	NA

2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30

Stockholders Equity 388.83 423.18 495.86 576.49 589.96 640.37 725.14 706.75 654.38 -61.33 -85.27 -101.40 -84.98

Common Stock Value 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NA NA NA NA

Additional Paid In Capital 831.94 819.31 808.13 794.57 776.53 760.64 746.35 730.77 712.62 NA NA 9.04 NA

Retained Earnings Accumulated Deficit -443.11 -396.14 -312.27 -218.07 -186.57 -120.27 -21.21 -24.02 -58.25 NA NA -110.44 NA

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 12.69 11.50 14.41 15.78 15.69 16.79 16.04 17.42 19.97 2.57 3.02 2.92 0.14

	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Stockholders Equity	388.83	423.18	495.86	576.49	589.96	640.37	725.14	706.75	654.38	-61.33	-85.27	-101.40	-84.98
Common Stock Value	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	NA	NA	NA	NA
Additional Paid In Capital	831.94	819.31	808.13	794.57	776.53	760.64	746.35	730.77	712.62	NA	NA	9.04	NA
Retained Earnings Accumulated Deficit	-443.11	-396.14	-312.27	-218.07	-186.57	-120.27	-21.21	-24.02	-58.25	NA	NA	-110.44	NA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value	12.69	11.50	14.41	15.78	15.69	16.79	16.04	17.42	19.97	2.57	3.02	2.92	0.14

2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30

Net Cash Provided By Used In Operating Activities -12.54 -42.66 -53.88 -51.70 -39.91 -51.83 31.52 8.85 19.51 -2.70 -35.11 151.90 NA

Net Cash Provided By Used In Investing Activities -3.66 -5.99 -8.32 -10.09 -18.27 -20.62 -14.05 -37.56 -19.27 -27.05 -31.84 -71.14 NA

Net Cash Provided By Used In Financing Activities -0.90 -1.00 -1.13 -1.87 -0.30 -3.39 -0.87 -6.17 206.01 163.14 56.64 -2.36 NA

	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Net Cash Provided By Used In Operating Activities	-12.54	-42.66	-53.88	-51.70	-39.91	-51.83	31.52	8.85	19.51	-2.70	-35.11	151.90	NA
Net Cash Provided By Used In Investing Activities	-3.66	-5.99	-8.32	-10.09	-18.27	-20.62	-14.05	-37.56	-19.27	-27.05	-31.84	-71.14	NA
Net Cash Provided By Used In Financing Activities	-0.90	-1.00	-1.13	-1.87	-0.30	-3.39	-0.87	-6.17	206.01	163.14	56.64	-2.36	NA

2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30

Net Cash Provided By Used In Operating Activities -12.54 -42.66 -53.88 -51.70 -39.91 -51.83 31.52 8.85 19.51 -2.70 -35.11 151.90 NA

Net Income Loss -46.97 -83.86 -94.20 -31.51 -66.30 -99.05 2.80 34.23 19.35 19.81 13.03 -19.54 -8.54

Depreciation Depletion And Amortization 13.57 12.36 12.06 11.95 11.40 10.98 10.61 6.43 11.58 9.62 4.88 1.92 NA

Increase Decrease In Inventories -5.19 -13.34 2.08 -58.85 -3.13 37.06 44.18 17.36 7.76 11.66 14.76 25.36 NA

Deferred Income Tax Expense Benefit NA NA NA 0.01 -1.26 NA NA 2.58 0.29 0.27 0.32 NA NA

Share Based Compensation 12.69 11.50 14.41 15.78 15.69 16.79 16.04 17.42 18.73 3.81 3.02 2.92 NA

	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Net Cash Provided By Used In Operating Activities	-12.54	-42.66	-53.88	-51.70	-39.91	-51.83	31.52	8.85	19.51	-2.70	-35.11	151.90	NA
Net Income Loss	-46.97	-83.86	-94.20	-31.51	-66.30	-99.05	2.80	34.23	19.35	19.81	13.03	-19.54	-8.54
Depreciation Depletion And Amortization	13.57	12.36	12.06	11.95	11.40	10.98	10.61	6.43	11.58	9.62	4.88	1.92	NA
Increase Decrease In Inventories	-5.19	-13.34	2.08	-58.85	-3.13	37.06	44.18	17.36	7.76	11.66	14.76	25.36	NA
Deferred Income Tax Expense Benefit	NA	NA	NA	0.01	-1.26	NA	NA	2.58	0.29	0.27	0.32	NA	NA
Share Based Compensation	12.69	11.50	14.41	15.78	15.69	16.79	16.04	17.42	18.73	3.81	3.02	2.92	NA

2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30

Net Cash Provided By Used In Investing Activities -3.66 -5.99 -8.32 -10.09 -18.27 -20.62 -14.05 -37.56 -19.27 -27.05 -31.84 -71.14 NA

Payments To Acquire Property Plant And Equipment 1.65 2.24 3.91 7.00 12.40 18.00 12.78 34.21 18.09 26.05 30.49 69.91 NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Net Cash Provided By Used In Investing Activities		-3.66	-5.99	-8.32	-10.09	-18.27	-20.62	-14.05	-37.56	-19.27	-27.05	-31.84	-71.14	NA
Payments To Acquire Property Plant And Equipment		1.65	2.24	3.91	7.00	12.40	18.00	12.78	34.21	18.09	26.05	30.49	69.91	NA

2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30

Net Cash Provided By Used In Financing Activities -0.90 -1.00 -1.13 -1.87 -0.30 -3.39 -0.87 -6.17 206.01 163.14 56.64 -2.36 NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Net Cash Provided By Used In Financing Activities		-0.90	-1.00	-1.13	-1.87	-0.30	-3.39	-0.87	-6.17	206.01	163.14	56.64	-2.36	NA

2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30

Revenues 17.48 9.90 24.77 146.78 69.59 87.70 179.41 192.51 223.68 137.42 64.50 13.26 4.73

Biomedical Advanced Research And Development Authority B A R D A, Grant And Other Revenue 2.70 2.10 0.10 0.90 2.90 3.30 2.00 1.30 0.90 0.00 0.00 0.00 2.60

Private Sector Customers, Product 14.34 7.30 24.01 52.22 65.88 80.53 175.84 104.03 94.01 32.39 2.41 4.39 2.13

Public Sector Entities, Product 0.42 0.29 0.48 93.49 0.78 3.82 1.61 87.25 128.59 105.03 62.09 8.87 0.00

Grant And Other Revenue 2.72 2.31 0.27 1.08 2.93 3.35 1.96 1.23 1.08 NA NA 0.00 2.60

Product 14.76 7.59 24.49 145.70 66.66 84.35 177.45 191.28 222.59 137.42 64.50 13.26 2.13

Service 0.30 NA NA NA 2.60 NA NA NA NA NA NA NA NA

Revenue From Contract With Customer Excluding Assessed Tax 17.48 9.90 24.77 146.78 69.59 87.70 179.41 192.51 223.68 137.42 64.50 13.26 4.73

Biomedical Advanced Research And Development Authority B A R D A, Grant And Other Revenue 2.70 2.10 0.10 0.90 2.90 3.30 2.00 1.30 0.90 0.00 0.00 0.00 2.60

Private Sector Customers, Product 14.34 7.30 24.01 52.22 65.88 80.53 175.84 104.03 94.01 32.39 2.41 4.39 2.13

Public Sector Entities, Product 0.42 0.29 0.48 93.49 0.78 3.82 1.61 87.25 128.59 105.03 62.09 8.87 0.00

Grant And Other Revenue 2.72 2.31 0.27 1.08 2.93 3.35 1.96 1.23 1.08 NA NA 0.00 2.60

Product 14.76 7.59 24.49 145.70 66.66 84.35 177.45 191.28 222.59 137.42 64.50 13.26 2.13

Service 0.30 NA NA NA 2.60 NA NA NA NA NA NA NA NA

Non Us 0.00 NA NA 1.30 1.80 4.00 3.50 NA NA NA NA NA NA

	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30
Revenues	17.48	9.90	24.77	146.78	69.59	87.70	179.41	192.51	223.68	137.42	64.50	13.26	4.73
Biomedical Advanced Research And Development Authority B A R D A, Grant And Other Revenue	2.70	2.10	0.10	0.90	2.90	3.30	2.00	1.30	0.90	0.00	0.00	0.00	2.60
Private Sector Customers, Product	14.34	7.30	24.01	52.22	65.88	80.53	175.84	104.03	94.01	32.39	2.41	4.39	2.13
Public Sector Entities, Product	0.42	0.29	0.48	93.49	0.78	3.82	1.61	87.25	128.59	105.03	62.09	8.87	0.00
Grant And Other Revenue	2.72	2.31	0.27	1.08	2.93	3.35	1.96	1.23	1.08	NA	NA	0.00	2.60
Product	14.76	7.59	24.49	145.70	66.66	84.35	177.45	191.28	222.59	137.42	64.50	13.26	2.13
Service	0.30	NA	NA	NA	2.60	NA	NA	NA	NA	NA	NA	NA	NA
Revenue From Contract With Customer Excluding Assessed Tax	17.48	9.90	24.77	146.78	69.59	87.70	179.41	192.51	223.68	137.42	64.50	13.26	4.73
Biomedical Advanced Research And Development Authority B A R D A, Grant And Other Revenue	2.70	2.10	0.10	0.90	2.90	3.30	2.00	1.30	0.90	0.00	0.00	0.00	2.60
Private Sector Customers, Product	14.34	7.30	24.01	52.22	65.88	80.53	175.84	104.03	94.01	32.39	2.41	4.39	2.13
Public Sector Entities, Product	0.42	0.29	0.48	93.49	0.78	3.82	1.61	87.25	128.59	105.03	62.09	8.87	0.00
Grant And Other Revenue	2.72	2.31	0.27	1.08	2.93	3.35	1.96	1.23	1.08	NA	NA	0.00	2.60
Product	14.76	7.59	24.49	145.70	66.66	84.35	177.45	191.28	222.59	137.42	64.50	13.26	2.13
Service	0.30	NA	NA	NA	2.60	NA	NA	NA	NA	NA	NA	NA	NA
Non Us	0.00	NA	NA	1.30	1.80	4.00	3.50	NA	NA	NA	NA	NA	NA

Plots across concepts

IncomeStatement

Expenses

Balance Sheet

Assets

Current Assets

NonCurrent Assets

Liabilities

Current Liabilities

Stockholders Equity

CashFlow

NetCashProvidedByUsedInOperatingActivities

NetCashProvidedByUsedInInvestingActivities

OperatingLeaseLiability

LesseeOperatingLeaseLiabilityPaymentsDue

FiniteLivedIntangibleAssets

InventoryNet

Line plots across dimensions of each concept

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:MajorCustomers, us-gaap:ProductOrService
(None, 'us-gaap:Product')

us-gaap:Revenues
us-gaap:ProductOrService
(None,)

us-gaap:Revenues
us-gaap:MajorCustomers, us-gaap:ProductOrService
(None, 'us-gaap:Product')

us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:AwardType, us-gaap:IncomeStatementLocation
('us-gaap:StockCompensationPlan', None)

us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)

us-gaap:FiniteLivedIntangibleAssetsNet
us-gaap:FiniteLivedIntangibleAssetsByMajorClass
(None,)